Healthcare >> Analyst Interviews >> October 2, 2018
Relatively Healthy Valuations for Development-Stage Companies
David Nierengarten, Ph.D., is Managing Director and Head of Healthcare Equity Research at Wedbush Securities. He is a senior biotechnology equity analyst with Wedbush Securities, mainly covering development-stage therapeutic companies. He began his career on the financial side of biotechnology at a venture capital firm that focused on early-stage therapeutic and medical device companies. Additionally, prior to joining Wedbush, Dr. Nierengarten gained experience on the other side of that equation, working in a clinical-stage, venture-backed biotechnology company, in business development and clinical trial operations. He received his bachelor’s degree in biochemistry from the University of Wisconsin-Madison and his Ph.D. in molecular and cell biology from the University of California-Berkeley.
Word count: 2,974
TWST: What is your coverage, and to what extent do you focus on gene-related technologies?
Dr. Nierengarten: About three-fourths of my list is